Both GIPR co-agonism (as in tirzepatide) and GIPR antagonism (as in MariTide, a bispecific hybrid molecule comprising two GLP-1R agonist peptides conjugated to a monoclonal anti-GIPR antagonistic antibody) are effective in treating people living with obesity 2,3,22
Court Decision Prevents Compounders from Producing Knockoffs of Novo Nordisks Semaglutide Grand View Research, UK GLP-1 Receptor Agonist Market Harvard University, GLP-1 Diabetes and Weight Loss Drug Side Effects: Ozempic Face and More Diabetes.org, How Many People in the UK Have Diabetes? CDC, National Diabetes Statistics Report WHO, Obesity and Overweight Health.com, Think GLP-1s Guarantee Weight Loss
These studies, while promising, cannot fully predict how the peptide will behave in human systems
L-carnitine supplementation: influence upon physiological function
Ratings for GPCR stock include 15 out of 18 ratings of Buy or equivalent